Valsartan

Valsartan Properties

Melting point	116-117°C
Boiling point	684.9±65.0 °C(Predicted)
Density	1.212±0.06 g/cm3(Predicted)
vapor pressure	0-0Pa at 20-25℃
storage temp.	2-8°C
solubility	DMSO: ≥20mg/mL
form	powder
pka	3.56±0.10(Predicted)
color	white to tan
optical activity	[α]/D -55 to -70°, c = 1 in methanol
Water Solubility	84.99mg/L(25 ºC)
Merck	14,9916
BCS Class	2
Stability	Hygroscopic
InChIKey	ACWBQPMHZXGDFX-QFIPXVFZSA-N
LogP	1.2-2.8 at 25℃ and pH2.5-7
Surface tension	59.6-68.1mN/m at 10-100mg/L and 20℃
Dissociation constant	3.76-4.38 at 25℃
CAS DataBase Reference	137862-53-4(CAS DataBase Reference)
FDA UNII	80M03YXJ7I
NCI Drug Dictionary	Diovan
ATC code	C09CA03
EPA Substance Registry System	L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (137862-53-4)

Pharmacokinetic data

Protein binding	94-97%
Excreted unchanged in urine	13%
Volume of distribution	17 Litres
Biological half-life	5-9 / Unchanged

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07,GHS08

Signal word

Warning

Hazard statements

H336-H361d

Precautionary statements

Hazard Codes

Risk Statements

Safety Statements

WGK Germany

3

RTECS

YV9455000

HS Code

29339900

NFPA 704

	0
1		0

Valsartan price More Price(51)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	PHR1315	Valsartan Pharmaceutical Secondary Standard; Certified Reference Material	137862-53-4	1g	$97.5	2024-03-01	Buy
Sigma-Aldrich	1708762	Valsartan United States Pharmacopeia (USP) Reference Standard	137862-53-4	350mg	$436	2024-03-01	Buy
TCI Chemical	V0112	Valsartan >98.0%(HPLC)(T)	137862-53-4	1g	$56	2024-03-01	Buy
TCI Chemical	V0112	Valsartan >98.0%(HPLC)(T)	137862-53-4	5g	$184	2024-03-01	Buy
Cayman Chemical	14178	Valsartan ≥98%	137862-53-4	10mg	$44	2024-03-01	Buy

Product number	Packaging	Price	Buy
PHR1315	1g	$97.5	Buy
1708762	350mg	$436	Buy
V0112	1g	$56	Buy
V0112	5g	$184	Buy
14178	10mg	$44	Buy

Valsartan Chemical Properties,Uses,Production

Indications and Usage

Valsartan (137862-53-4) is a type of specific angiotensin I (AT1) receptor antagonist and a clinical non-dermal AT1 receptor antagonist following losartan that has important effects in adjusting bodily blood pressure and maintaining electrolyte-body fluid balance. Valsartan’s antihypertensive effects are stronger than those of enalapril and is suitable for treating hypertension, mild to moderate primary hypertension, and especially secondary hypertension caused by renal damage. It can significantly reduce proteinuria for hypertension patients with diabetes or normal liver functions, and it can promote uric acid and urinary sodium to protect the kidney. Valsartan is also suitable for reducing the cardiovascular mortality for high risk patients (left ventricular failure or dysfunction) after experiencing a heart attack.

Mechanisms of Action

Valsartan (137862-53-4) selectively affects the AT1 receptor subtype and prevents AT1 from binding with AT1 receptors (its selective AT1 receptor antagonizing effect is about 20000 times greater than its effects on AT2 receptors), thus inhibiting vasoconstriction and aldosterone release, producing an antihypertensive effect, but it cannot inhibit the release of aldosterone caused by potassium ions (K+). Valsartan does not affect angiotensin-converting enzymes (ACE) or renin and its receptors, and it does not inhibit ion channels related to blood pressure regulation and sodium balance. Valsartan does not inhibit ACE and does not affect bodily bradykinin levels, thus causing less coughing side effects than ACE inhibitors. Valsartan does not affect heart rate when lowering blood pressure. Sudden ceasing in Valsartan use will not cause rebound hypertension or other side effects. Valsartan does not affect hypertension patients’ overall cholesterol, triglyceride, blood glucose, or uric acid levels.

Pharmacokinetics

For most patients, a single oral dose will have antihypertensive effects that occur within 2 hours, peak at 4-6 hours, and continue for over 24 hours. 2-4 weeks of treatment will result in maximum hypertensive curative effects, which will last throughout long-term treatment. It can be used with thiazide diuretics to further strengthen antihypertensive effects.

Clinical Research

A clinical trial showed that Valsartan has very noticeable effects on mild to moderate hypertension. A daily dose of ≥80 mg can effectively control systolic and diastolic blood pressure while not affecting blood pressure’s circadian rhythm; a daily 160mg dose has more noticeable effects than a daily 100mg dose of losartan. Moderate hypertension patients with intact renal functions have a good tolerance towards Valsartan, Valsartan’s curative effects are significantly superior to those of ACE inhibitors, and there are minimal adverse reactions. Effective in treating severe hypertension when combined with other antihypertensive drugs.

Description

Diovan(Valsartan) was launched in Germany and the UK as an angiotensin Ⅱ antagonist for use as an antihypertensive agent. Biphenylbromomethyl nitrite serves as the starting material for a three step synthesis of the compound, in which the (S)- enantiomer is more active than the (R)-enantiomer. Valsartan is a nonpeptide drug which is a highly specific antagonist of the AT₁ receptor and is potent and orally active. This receptor is responsible for angiotensin Ⅱ cardiovascular effects (aldosterone and catecholamine secretion, vascular constriction, positive inotropic response and renal effects). Unlike losartan, it is not a prodrug and a single daily dose is comparible in activity to the ACE drug enalapril. It also did not exhibit the coughing side effect observed with ACE inhibitors. Diovan(Valsartan) is slowly metabolized (long lasting) with its main metabolite being significantly less active. There was no evidence of rebound hypertension when drug treatment was terminated and was as effective as the dihydropyridine Ca antagonist anlodipine.

Chemical Properties

White Crystalline Powder

Originator

Norvartis (Switzerland)

Uses

Valsartan is used as a first-line drug for the treatment of uncomplicated hypertension, isolated systolic hypertension, and left ventricular hypertrophy. Valsartan is a clinically widely used antihypertensive agent with the advantages of low side effects and good tolerability, and can also be used for the treatment of hypertension in patients with diabetes and renal disease.

Definition

ChEBI: A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.

brand name

Diovan (Novartis).

Therapeutic Function

Antihypertensive

General Description

Valsartan, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Diovan), likelosartan, possesses the acidic tetrazole system, which mostlikely plays a role, similar to that of the acidic groups of angiotensinII, in binding to the angiotensin II receptor. In addition,the biphenyl system that serves to separate the tetrazolefrom the aliphatic nitrogen is still present. In addition, there isa carboxylic acid side chain in the valine moiety that alsoserves to bind to the angiotensin II receptor.

Biochem/physiol Actions

Valsartan is an Angiotensin II type 1 (AT1) receptor antagonist and anti-hypertensive. Valsartan renders protection against heart attack and stroke resulting from abrupt increase in blood pressure. Valsartan reduces myocardial-infarction-related complications in heart attack survivors.

Synthesis

An aqueous solution (120 ml) of potassium hydroxide (0.568 mol, 31.8 g) is added in succession with 2-[(4-bromo-benzyl)-pentanoyl-amino]-3-methyl-butyric acid (0.811 mol, 30.0 g), tetrahydrofuran (120 ml), triphenylphosphine (0.0121 mol, 3.2 g) and palladium acetate (0.00405 mol, 0.91 g). The reaction mixture is refluxed and added with 2-(2H-tetrazol-5-yl)-benzene-boronic acid (0.142 mol, 27.0 g) in portions in about 6 h. After completion of the addition, the mixture is left to react for 2h, then cooled to room temperature and the phases are separated. The organic phase is diluted with water (120 ml) and tetrahydrofuran is distilled off under reduced pressure. The remaining aqueous solution is acidified to pH 6.5 and washed with isopropyl acetate (60 ml). The aqueous phase is acidified to pH 2 and diluted with isopropyl acetate (60 ml), the diphasic solution is filtered to remove phenyltetrazol. Phases are separated and the organic phase is concentrated under reduced pressure, to obtain a thick oil that is crystallized from isopropyl acetate (90 ml) and heptane (150 ml). The resulting product is filtered, washed twice with a 1:1 isopropyl acetate/heptane mixture (30 ml), and dried in static dryer at 45°C to obtain 28.2 g of Valsartan.

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia, hypotension and renal impairment with ACE-Is and aliskiren.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Lithium: reduced excretion (possibility of enhanced lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Metabolism

Valsartan is not highly metabolised as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.
Valsartan is mainly eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug.

storage

Store at RT

References

1) Criscione?et al. (1993),?Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype; Br. J. Pharmacol.,?110?761 2) Wexler?et al. (1996), Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy; J. Med. Chem.,?39?625 3) Iwashita?et al. (2013),?Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice; Adipocyte,?2?28

Valsartan synthesis

Synthesis of Valsartan from (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido

Valsartan Preparation Products And Raw materials

Raw materials

Tetrazole L-Valine methyl ester hydrochloride 4'-formylbiphenyl-2-carbonitrile Valeryl chloride Sodium cyanoborohydride

Tributyltin azide Triethylamine N-[(2′-(1-Triphenylmethyl-Tetrazole-5-Yl)Biphenyl-4-Yl]-Methyl]-N-Valeryl-L- Valine Benzyl Ester N-(4-bromobenzyl)-N-pentanoyl-L-valine 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole

Valsartan cyano analog methyl ester (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine benzyl ester Valsartan Methyl Ester

1of3

Preparation Products

Valsartan Suppliers

Global( 1019)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
APOLLO HEALTHCARE RESOURCES	+6596580999	sales@apollo-healthcare.com.sg	Singapore	399	58
Hebei Weibang Biotechnology Co., Ltd	+8615531157085	abby@weibangbio.com	China	8811	58
Shaanxi Dideu Medichem Co. Ltd	+86-29-81148696 +86-15536356810	1022@dideu.com	China	3882	58
Hebei Mojin Biotechnology Co., Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12839	58
Hebei Chuanghai Biotechnology Co,.LTD	+86-13131129325	sales1@chuanghaibio.com	China	5892	58
Hebei Dangtong Import and export Co LTD	+86-13910575315 +86-13910575315	admin@hbdangtong.com	China	1000	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2472	58
Sigma Audley	+86-15937194204 +86-18126314766	nova@sh-teruiop.com	China	467	58
Hangzhou Hyper Chemicals Limited	+86-0086-57187702781 +8613675893055	info@hyper-chem.com	China	295	58
Shaanxi TNJONE Pharmaceutical Co., Ltd	+8618092446649	sarah@tnjone.com	China	1143	58

Supplier	Advantage
APOLLO HEALTHCARE RESOURCES	58
Hebei Weibang Biotechnology Co., Ltd	58
Shaanxi Dideu Medichem Co. Ltd	58
Hebei Mojin Biotechnology Co., Ltd	58
Hebei Chuanghai Biotechnology Co,.LTD	58
Hebei Dangtong Import and export Co LTD	58
Henan Bao Enluo International TradeCo.，LTD	58
Sigma Audley	58
Hangzhou Hyper Chemicals Limited	58
Shaanxi TNJONE Pharmaceutical Co., Ltd	58

Related Qustion

Q:What are the side effects of Valsartan?
A:ommon side effects of Valsartan include: shortness of breath, cough , dizziness and light-headedness on waking, nausea, fatigu....
Jan 8，2024

View Lastest Price from Valsartan manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2024-11-25	Valsartan 137862-53-4	US $0.00-0.00 / Kg/Bag	1Kg/Bag	EP / USP / JP	20 tons	Sinoway Industrial co., ltd.
2024-11-25	Valsartan 137862-53-4	US $1.00 / g	1g	99	2000	Jinan Jianfeng Chemical Co., Ltd
2024-11-25	Valsartan 137862-53-4	US $999.00-666.00 / kg	1kg	99%	5000	HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD

Valsartan
137862-53-4
US $0.00-0.00 / Kg/Bag
EP / USP / JP
Sinoway Industrial co., ltd.

Valsartan
137862-53-4
US $1.00 / g
99
Jinan Jianfeng Chemical Co., Ltd

Valsartan
137862-53-4
US $999.00-666.00 / kg
99%
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD

Valsartan Spectrum

Valsartan(137862-53-4)¹HNMR

137862-53-4(Valsartan)Related Search:

Telmisartan Valsartan D9 Valsartan Benzyl Ester N2-Trityl Analog L-VALINE, N-[(2'-CYANO[1,1'-BIPHENYL]-4-YL)METHYL]-, METHYL ESTER, MONOHYDROCHLORIDE L-VALINE METHYL ESTER HYDROCHLORIDE (INTERMEDIATE OF VALSARTAN)

N-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-L-valine methyl ester Valsartan Benzyl Ester N1-Trityl Analog Valsartan for peak identification Valsartan for system suitability N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine benzyl ester

(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate 1426129-50-1 enantioMer BOC-D-4,4'-BIPHENYLALANINE Telmisartan Impurity 10 N-NITROSO-DI-ISO-PROPYLAMINE

LCZ-696 Impurity 60 Valsartan Impurity 32 (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoate

1of4

L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- Ambroxol Hydrochloride Imp.D 3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic aci (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]amine (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic aci VALSARTAN IMP C Valsartan,99%e.e. N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE VALSARTAN CGP-48933 VALSARTAN, MM STANDARD VALSARTAN, USP STANDARD VALSARTAN, RELATED COMPOUND A(R)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE USP STANDARD VALSARTAN, RELATED COMPOUND C(S)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE BENZYL ESTER USP STANDARD Valsartan99% N-[[(2-Cyano(1.1-Biphenyl)-4-Yl)Methyl]MethylEster]-L-Valine.Hydrochloride ValsartanC24H29N503 Valsartane (S)-2-(N-((2''-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID Diovan, N-(1-Oxopentyl)-N-[[2(1H-tetrazol-5-yl)[1,1biphenyl]-4-yl]methyl]-L-valine, CGP-48933 N-(1-N.PENTANOYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1'',1- BIPHENYL]-4-YL]METHYL]-L-VALINE/VALSARTAN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) Tareg 3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid Valsartan Related Compound A (10 mg) ((R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine) N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'- N-(1-Oxopentyl)-N-[[2’-(1H-tetrazol-5-y1)[1，1'-biphenyl]-4-y1]methyl]-L-valine N-(1-Oxopentyl)-N-[[2'-(2H-tetrazo-5-yl) Valsartan (350 mg)G0F0650.997mg/mg(an) Valsartan (350 mg) 3-Methyl-2-[pentanoy L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid Valsartan API Valsartan (>99% pure) N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine (2S)-3-Methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}Methyl)pentanaMido]butanoic acid L-Valsartan 2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid ((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-L-valine N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3 -methylbutanoic acid (S)-N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid Valsartan, 99%, a nonpeptide angiotensin II AT1 receptor antagonist Valsartan 3-Methyl-2-[pentanoyl-[[4- [2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl] amino]-butanoic acid Valsartan Manufacturer (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid Valsatarn Valsartan Impurity 18 (S)-2-(N-((2'-(1H-tetrazol-5-yl) Valsartan CRS Valsartan RS Valsartan for peak identification CRS Valsartan for system suitability CRS N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine N-((2-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine Valsartan USP/EP/BP